The mouse lymphoma TK assay (MLA) is part of an in vitro battery of tests designed to predict risk assessment prior to in vivo testing.

Here we describe in detail the protocol for the production of mouse CAR T cells, establishing lymphoma in syngeneic mice, and treatment of lymphoma with CAR T cells with or without the use of lymphodepleting pre-conditioning.

Recent advances in genetic engineering have made it possible to develop transgenic mouse models recapitulating major known modifications of the genome and to infect mice with viruses that can induce B-cell lymphomas.

Genetics also play a major role in mouse lymphomagenesis and leukemogenesis. The most potent chemical carcinogens require only a single injection in young mice to induce a high incidence of lymphomas, often thymic T-cell lymphoblastic lymphomas.

Immunodeficient mice are susceptible to spontaneous tumors which are rarely reported in patient-derived tumor xenografts (PDX) studies. Quality control of PDX identity is required at each step on the preclinical assays to avoid erroneous conclusions.

2006年7月10日 · The follicular/pleomorphic lymphoma, the most common lymphoma in most strains of mice, was previously termed reticulum cell sarcoma, centrocytic/centroblastic lymphoma and follicular center cell lymphoma (Jones et al., 1990; Frith et al., 1996).

2019年3月8日 · Mouse models are significant in the development of new lymphoma treatments, because they are used to identify key drug targets and serve as models for preclinical drug testing.

2024年10月19日 · Mouse models are an indispensable tool in lymphoma research. Here, we focus on the utilization of genetically engineered mouse models as preclinical avatars in lymphoma research. We describe lymphoma-relevant alleles and allele combinations, as well as general considerations for model selection.

2021年8月12日 · Genetically engineered mouse models (GEMM) that faithfully recapitulate lymphoma-associated genetic alterations offer a valuable platform to investigate the pathogenic roles of candidate oncogenes and tumor suppressors in vivo, and to pre-clinically develop new therapeutic principles in the context of an intact tumor immune microenvironment.

Diffuse large B cell lymphoma (DLBCL) is the most diagnosed, aggressive non-Hodgkin lymphoma, a type of blood cancer. In this study, we developed new DLBCL cell-derived xenograft mouse models.